Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-388

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Roche · Phase 2 · Completed · Enrollment 447

NCT06628362

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Arm 1: Placebon/rn/rn/rn/r
Arm 2: Enicepatide Dose Level 1 (Low)n/rn/rn/rn/r
Arm 3: Enicepatide Dose Level 2n/rn/rn/rn/r
Arm 4: Enicepatide Dose Level 3n/rn/rn/rn/r
Arm 5: Enicepatide Dose Level 4 (High)n/rn/rn/rn/r

Not shown

  • Arm 1: Placebo: endpoint not reported
  • Arm 2: Enicepatide Dose Level 1 (Low): endpoint not reported
  • Arm 3: Enicepatide Dose Level 2: endpoint not reported
  • Arm 4: Enicepatide Dose Level 3: endpoint not reported
  • Arm 5: Enicepatide Dose Level 4 (High): endpoint not reported